Fresenius SE & Co. KGaA 11/6/2024 Earnings Report $11.03 +0.03 (+0.29%) As of 03:59 PM Eastern Earnings HistoryForecast Fresenius SE & Co. KGaA EPS ResultsActual EPS$0.19Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AFresenius SE & Co. KGaA Revenue ResultsActual Revenue$5.90 billionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AFresenius SE & Co. KGaA Announcement DetailsQuarterDate11/6/2024TimeBefore Market OpensConference Call ResourcesFSNUY Earnings History Remove Ads Fresenius SE & Co. KGaA Earnings HeadlinesFresenius Raises €1.1 Billion for Stake in Dialysis CompanyMarch 4 at 9:50 AM | finance.yahoo.comFresenius Continues Growth of Biosimilars Portfolio with the U.S. Availability of Otulfi® (ustekinumab-aauz)March 3, 2025 | finance.yahoo.comTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth protection guide shows you how to use Trump's vision to lock down your savings—your freedom, your future. Plus, for a few lucky individuals, we're honoring Trump's historic return with an exclusive free gift. March 7, 2025 | American Alternative (Ad)Fresenius Seeks €1.1 Billion for Stake in Dialysis CompanyMarch 3, 2025 | bloomberg.comFresenius SE & Co. KGaA (0OO9) Gets a Hold from Goldman SachsFebruary 26, 2025 | markets.businessinsider.comFresenius Sees Hospital Costs Holding Back Higher Profit in 2025February 26, 2025 | financialpost.comSee More Fresenius SE & Co. KGaA Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Fresenius SE & Co. KGaA? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fresenius SE & Co. KGaA and other key companies, straight to your email. Email Address About Fresenius SE & Co. KGaAFresenius SE & Co. KGaA (OTCMKTS:FSNUY), a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.View Fresenius SE & Co. KGaA ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Analysts Lift Archer Aviation Stock Despite Earnings Miss DigitalOcean Rides Cloud Wave and AI Hype to Strong EarningsPrice Targets on NVIDIA Rise in Front of EarningsThe Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance? Upcoming Earnings Oracle (3/10/2025)Adobe (3/12/2025)PDD (3/19/2025)Micron Technology (3/20/2025)Accenture (3/20/2025)FedEx (3/20/2025)NIKE (3/20/2025)Cintas (3/26/2025)Paychex (4/1/2025)Bank of New York Mellon (4/11/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
